RU2016126176A3 - - Google Patents

Download PDF

Info

Publication number
RU2016126176A3
RU2016126176A3 RU2016126176A RU2016126176A RU2016126176A3 RU 2016126176 A3 RU2016126176 A3 RU 2016126176A3 RU 2016126176 A RU2016126176 A RU 2016126176A RU 2016126176 A RU2016126176 A RU 2016126176A RU 2016126176 A3 RU2016126176 A3 RU 2016126176A3
Authority
RU
Russia
Application number
RU2016126176A
Other languages
Russian (ru)
Other versions
RU2648236C2 (ru
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/077124 external-priority patent/WO2015086642A1/en
Publication of RU2016126176A3 publication Critical patent/RU2016126176A3/ru
Application granted granted Critical
Publication of RU2648236C2 publication Critical patent/RU2648236C2/ru

Links

RU2016126176A 2013-12-13 2014-12-10 Ингибиторы тирозинкиназы брутона RU2648236C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915582P 2013-12-13 2013-12-13
US61/915,582 2013-12-13
PCT/EP2014/077124 WO2015086642A1 (en) 2013-12-13 2014-12-10 Inhibitors of bruton's tyrosine kinase

Publications (2)

Publication Number Publication Date
RU2016126176A3 true RU2016126176A3 (enExample) 2018-01-18
RU2648236C2 RU2648236C2 (ru) 2018-03-23

Family

ID=52016584

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016126176A RU2648236C2 (ru) 2013-12-13 2014-12-10 Ингибиторы тирозинкиназы брутона

Country Status (10)

Country Link
US (1) US9556150B2 (enExample)
EP (1) EP3080099B1 (enExample)
JP (1) JP6219523B2 (enExample)
KR (1) KR101768402B1 (enExample)
CN (1) CN105793252B (enExample)
CA (1) CA2931189C (enExample)
MX (1) MX374758B (enExample)
RU (1) RU2648236C2 (enExample)
TW (1) TW201534600A (enExample)
WO (1) WO2015086642A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9624201B2 (en) * 2013-12-13 2017-04-18 Hoffmann-La Roche Inc. Inhibitors of bruton's tyrosine kinase
WO2015099127A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 Fgfrゲートキーパー変異遺伝子およびそれを標的とする医薬
JP6762300B2 (ja) 2015-06-17 2020-09-30 中外製薬株式会社 アミノピラゾール誘導体
IL293821A (en) 2015-07-02 2022-08-01 Acerta Pharma Bv Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
WO2018152434A1 (en) * 2017-02-17 2018-08-23 The Regents Of The University Of California Systems and methods for making assignments in isotope-labelled proteins using nuclear magnetic resonance data
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2025175249A1 (en) 2024-02-14 2025-08-21 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527819A (en) 1991-09-06 1996-06-18 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
FR2772763B1 (fr) 1997-12-24 2004-01-23 Sod Conseils Rech Applic Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
US6316466B1 (en) 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
US20030236288A1 (en) 2002-02-28 2003-12-25 Karl Schoenafinger Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
UA79804C2 (en) 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
CN1934074A (zh) 2003-06-24 2007-03-21 尤尼罗亚尔化学公司 杀真菌的苯氧基苯肼衍生物
JP4705630B2 (ja) 2004-03-26 2011-06-22 エフ.ホフマン−ラ ロシュ アーゲー テトラヒドロカルバゾール及び誘導体
WO2006072828A2 (en) 2005-01-07 2006-07-13 Pfizer Products Inc. Heteroaromatic quinoline compounds and their use as pde10 inhibitors
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique
US8629147B2 (en) 2005-11-03 2014-01-14 Chembridge Corporation Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
JP2009516702A (ja) 2005-11-18 2009-04-23 スミスクライン・ビーチャム・コーポレイション 化合物
US8115005B2 (en) 2006-08-04 2012-02-14 Decode Genetics Ehf. Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation
CN101679408B (zh) 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
AU2008235455A1 (en) 2007-04-06 2008-10-16 Novartis Ag 2, 6-naphthyridine derivatives as protein kinase modulators
EP2164840A2 (en) 2007-05-09 2010-03-24 Vertex Pharmaceuticals Incorporated Modulators of cftr
US8026257B2 (en) 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
PE20100851A1 (es) * 2008-06-24 2011-01-31 Hoffmann La Roche PIRIDIN-2-ONAS Y PIRIDAZIN-3-ONAS SUSTITUIDAS COMO INHIBIDORES DE Btk
HRP20151258T1 (hr) * 2009-08-07 2016-02-26 Chugai Seiyaku Kabushiki Kaisha Derivat aminopirazola
US9840515B2 (en) 2010-12-09 2017-12-12 University of Pittsburgh—of the Commonwealth System of Higher Education Protein kinase D inhibitors
JP5620417B2 (ja) 2011-02-07 2014-11-05 中外製薬株式会社 アミノピラゾール誘導体を含む医薬

Similar Documents

Publication Publication Date Title
BR112021000792B8 (enExample)
BR122022002075A2 (enExample)
AT524874A5 (enExample)
AT524834A2 (enExample)
AU2018438767B1 (enExample)
AT521543A3 (enExample)
AT524266A2 (enExample)
BR102019026286B1 (pt) Método e aparelho para o avanço de produtos a serem moldados
BR102019025884B1 (pt) Sistema de segurança aprimorado para máquinas de operação de autopropulsão
BR102019023514B1 (pt) Método para determinar a massa de ar preso em cada cilindro de um motor a combustão interna
BR112021001434B1 (pt) Aço com alto teor de manganês e método de produção do mesmo
BR112021001374B1 (pt) Composição farmacêutica para o tratamento da hipertensão e seu uso
BR112021001128B1 (pt) Composição de cimento para impressão 3d, método de impressão 3d, kit para a preparação de uma composição de cimento para impressão 3d e método de impressão 3d implementando o kit
BR112021001186B1 (pt) Aparelho para o tratamento de celulite para tratar expressões de celulite na pele de um paciente associadas a um local de tratamento de septos
BR112021000922B1 (pt) Tela de filtro, e, método para purificar água de alimentação
BR112020026077B1 (pt) Recipiente com estrutura encaixável
BR102019012845B1 (pt) Montagens de guia de entrada de piso de compartimento de carga retráteis para carregamentos paletizados em aeronaves de carga e aeronave e carga
BR112020023832B1 (pt) Amostra de calibração de sistemas de análise multiespectral e método para calibração de sistemas de análise multiespectral
BR112020024987B1 (pt) Método, montagem e sistema para prover uma estrutura de base, método industrial, e, braço mecânico
BR112020023823B1 (pt) Distribuidor
BR112020022482B1 (pt) Composição, anticorpo anti-cd24, anticorpo biespecífico e receptor de antígeno quimérico
BR112020022658B1 (pt) Método para estimar um nível de pressão sonora, sistema de fone de ouvido, fone de ouvido e uso do fone de ouvido
BR112020022516B1 (pt) Processo para degomagem enzimática de óleo
BR112020021042B1 (pt) Compostos de carboxamidas bicíclicas, composição farmacêutica e uso das mesmas
BR112020020812B1 (pt) Composições de tratamento de superfícies duras, seu uso, método para proporcionar ação antimicrobiana residual e substrato relacionado